Drug Information Association Logo
Corporate Tagline

Evaluation and Management of Cardiac Conditions in Oncology Patients

| Online

« Back to Listing

Overview 

Continuing Education credit or Certificate Program units are not available for Archived Webinars


Cardio-oncology focuses on cardiovascular safety monitoring and management of cardiovascular toxicities of oncology drugs during development and post-approval. The discipline evolved as there is a prevalence of cardiotoxicities associated with cancer therapeutics and a need for clearly defined cardiovascular risk management for their development. This two-part webinar series will review different critical topics in the evaluation and management of cardiac conditions in oncology patients.

Part I: Updates in Cardio-oncology
This webinar will present topics critical to the evaluation of cardiac safety as it pertains to oncology drug development, and will provide an understanding of the investigations in the unique setting of drug therapy for treatment of cancer patients. Issues such as QT evaluation, troponin monitoring, and cardiac imaging will also be reviewed.

Part II: Treatments
This webinar will expand on the learnings from part I and discuss the cardiac evaluation of patients in the clinic – both in drug development as well as in oncology clinical practice.  The presentations will be followed by a question and answer period which will allow participants to get further explanations on managing these challenging cardiovascular issues from people actively engaged in this area.





This webinar was developed in collaboration with the Cardiac Safety Research Consortium


This archived webinar will be available for purchase through November 30, 2014.

Featured Topics 

Part I:  Updates in Cardio-oncology

Co-Moderators: 
Daniel Lenihan MD, FACC
Professor, Division of Cardiovascular Medicine
Director, Cardiovascular Clinical Research
Vanderbilt University

John Finkle MD, FACC, FACP
Vice President, Clinical Safety and Pharmacovigilance
GlaxoSmithKline

Speakers:
QT Interval Evaluation During Oncology Drug Development
John Finkle MD, FACC, FACP
GlaxoSmithKline

Use of Troponin and Other Biomarkers in Oncology Patients
Daniel Lenihan, MD
Vanderbilt University

Cardiac Imaging (Echo, MRI)
Juan Carlos Plana, MD
Cleveland Clinic


Part II: Treatments

Co-Moderators:  
John Finkle, MD FACC FACP
Vice President, Clinical Safety and Pharmacovigilance
GlaxoSmithKline

Daniel Lenihan MD, FACC
Professor, Division of Cardiovascular Medicine
Director, Cardiovascular Clinical Research
Vanderbilt University

Speakers:
Follow Up of CV events
Mary Beth Sabol, MD
Safety Development Leader
Global Clinical Safety and Pharmacovigilance
GlaxoSmithKline

Blood Pressure Management During Anti-angiogenic Therapy for Cancer
Philip Sager, MD, FACC, FAHA, FHRS
Consulting Professor of Medicine, Stanford University
President, Sager Consulting Experts, Inc.
Chair, Scientific Program’s Committee, Cardiac Safety Research Consortium

Optional Management of Cardio-toxicity During Drug Development
Joseph Carver, MD
Senior Administrative Officer, Cardiology
Abramson Cancer Center

Who Should Attend 

Professionals with intermediate to advanced knowledge of, and experience in:

  • Safety / Pharmacovigilance
  • Drug Development
  • Risk Management

Learning Objectives 

Part I: Updates in Cardio-oncology
At the conclusion of this webinar, participants should be able to:

  • Evaluate the electrocardiographic QT interval during oncology drug development
  • Describe the practical aspects of using cardiac troponin levels and other biomarkers to detect and monitor for cardiotoxicity in oncology drug development
  • Discuss the practical aspects of cardiac imaging modalities to monitor cardiotoxicity in oncology drug development

Part II: Treatments
At the conclusion of this webinar, participants should be able to:

  • Explain the benefits of cardioprotective therapy for the prevention of cardiotoxicity during cancer chemotherapy
  • Recognize the practical aspects of improved follow-up of cardiovascular events in oncology drug development
  • Discuss the optimal evaluation and management of blood pressure during therapy with anti-angiogenic agents

Contact Information 

Registration Questions and Technical Support Day of Event
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100
Fax: +1.215.442.6199
CustomerService@diahome.org

Questions on Archived Webinar
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199
Jessica.Culp@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Technical Support Day of Event
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100
CustomerService@diahome.org

Presenter(s) 

Previous Next

Agenda  

Day 1 Thursday, Dec 12, 2013

  • 7:00AM - 11:59PM

    Evaluation and Management of Cardiac Conditions in Oncology Patients


    Session Chair(s):

    • Daniel J. Lenihan, DrMed, FACC
      Director, Cardiovascular Clinical Research; Prof, Div. Cardiovascular Medicine
      Vanderbilt University, United States
    • John K. Finkle, MD
      Vice President, Clinical Safety and Pharmacovigilance
      GlaxoSmithKline, United States

    Speaker(s):

    • Use of Troponin and Other Biomarkers in Oncology Patients
      Daniel J. Lenihan, DrMed, FACC
      Director, Cardiovascular Clinical Research; Prof, Div. Cardiovascular Medicine
      Vanderbilt University, United States
    • Evaluation of Cardiac Repolarization in Oncology Drug Development
      John K. Finkle, MD
      Vice President, Clinical Safety and Pharmacovigilance
      GlaxoSmithKline, United States
    • Juan Carlos Plana, MD
      Cardiovascular Staff Physician
      Cleveland Clinic, United States
    • Follow Up of Cardiovascular Events
      Mary Beth Sabol, MD
      United States
    • Philip T. Sager, MD, FACC
      President; CVI Consulting Professor, Stanford University School of Medicine
      Sager Consulting Experts , United States
    • Optimal Management of Cardiac Toxicity During Drug Development:The Role of CardiOncology
      Joseph R Carver
      Senior Administrative Officer
      Abramson Cancer Center, United States
  • 7:00AM - 11:59PM

    Part I: Updates in Cardio-oncology
  • 7:00AM - 11:59PM

    Part II: Treatments

Registration Fees 

Other Fees

Group Site
$999.00
Group Plus
$1195.00

Member

Member Government Individual
$225.00
Member Academia Individual
$275.00
Member Individual
$350.00

Non-Member

NonMember Government Individual
$225.00
NonMember Academia Individual
$275.00
NonMember Individual
$395.00
Registration Fees for Additional Offerings
Part II: Treatments - Standard Rate
$0.00
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.


Cancellations
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top